Check out the fantastic news from our portfolio company Structure Therapeutics (NASDAQ: GPCR)! The company announced positive 12-week topline obesity data from its Phase 2a study of GSBR-1290, along with positive topline results from its capsule to tablet PK study. Both studies achieved their primary and secondary objectives. Topline results include that in the Phase 2a obesity study, GSBR-1290 demonstrated a clinically meaningful and statistically significant placebo-adjusted mean decrease in weight of 6.2%1 (p<0.0001) at 12 weeks; A capsule to tablet PK study designed to explore a new tablet formulation of GSBR-1290 demonstrated a placebo-adjusted mean weight loss of up to 6.9% (p<0.0001) with the tablet formulation at 12 weeks; GSBR-1290 demonstrated generally favorable safety and tolerability results following repeated, daily dosing up to 120mg. #MedicalInnovation #ObesityResearch #ClinicalTrials #QimingPortfolio #QimingHealthcare
We're pleased to share positive topline data from our 12-week Phase 2a #obesity study of our oral, non-peptide GLP-1 receptor agonist, GSBR-1290, along with positive data from our capsule to tablet PK study. GSBR-1290 demonstrated clinically meaningful and statistically significant weight loss and generally favorable safety and tolerability result. We look forward to starting our Phase 2b study, which is on track to begin in the fourth quarter of this year. Read the full announcement here: https://lnkd.in/eJp_qPuS
